Inverness Medical Innovations (Waltham, Massachusetts) continues an acquisition spree that started several years ago, now reporting its fourth major deal since the start of the new year. It has entered into a binding agreement with Kroll (Gretna, Louisiana), a subsidiary of Marsh and McLennan (New York), to purchase its Substance Abuse Testing division called Kroll Laboratory Specialists for $110 million in cash. (Medical Device Daily)
Just a little zap and temporary pores open. Inovio Biomedical (San Diego) is banking on this process, known as electroporation, to substantially change vaccine delivery. It has just unveiled a new clinical-grade, miniaturized device designed to deliver a variety of DNA vaccines, opening the door to push its healthy pipeline of new-style preventive and therapeutic vaccines into human trials. (Medical Device Daily)